Immutep (IMMP) has released an update.
Immutep Limited has successfully completed its Retail Entitlement Offer, raising approximately A$10.6 million, as part of a broader effort to secure A$100.2 million in funding through combined offerings to retail and institutional investors. The company achieved a 62% take-up rate from its eligible retail shareholders, demonstrating solid support and anticipation for its advancement towards marketing approval for eftilagimod alpha (efti) through its late-stage clinical trials, including a Phase III trial for lung cancer. Shares from this offer are expected to begin trading on the ASX shortly, contributing to Immutep’s ongoing development of innovative LAG-3 immunotherapies for cancer and autoimmune diseases.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
